# Capacity/distribution expansion to help tide over high competition; BUY

CMP (Rs): 478 | TP (Rs): 800

Retail > Company Update > March 13, 2025

Our analysis of CY24 AR suggests that VBL is making big investments to capture industry tailwinds, expand new categories, and ramp-up its presence in Africa, with recent acquisition of rights for South Africa/Tanzania regions. With likely commissioning of 4 more plants, VBL's peak-month capacity is ~65% higher ahead of CY25 season vs CY22, which remains a big edge in times of high competitive intensity. In addition, focus remains on serving the market better with consolidation of distributors and distribution expansion with accelerated visi-cooler placements (up ~15% in CY24). Initial trends in acquired territories is encouraging with South Africa delivering double-digit growth in CY24 and Tanzania seeing growth acceleration with introduction of new PET lines (vs glass). Among other major geographies, Sri-Lanka is back on a strong growth trajectory, Zimbabwe should see growth revival in CY25 after implementation of Sugar Tax in mid-CY24, while Morocco continues to see robust trends. With an ESG focus, VBL is light-weighting its SKUs, reducing sugar/water usage, and investing in renewable energy, which are enabling growth and driving margin gains. Operating cash flows remain healthy at 85-90% of post-tax EBITDA, while capacity expansion drove negative FCF. RPTs aligned with historical trends in CY24. We remain confident of continued healthy growth trends for VBL, albeit heightened competitive intensity can impact near-term margin of the India business. We maintain BUY on upgrade potential to street numbers.

**Big capacity/distribution expansion provides scope for earnings beat:** Through the CY22-CY25 seasons, VBL has incurred a capex of ~Rs100bn toward 10 greenfield plants (incl CWIP plants in Buxar, Mandi, Gorakhpur, and Meghalaya), and 9 brownfield expansions (incl international). Such big investments have expanded VBL's capacity by ~65% over CY22-25 and a normal summer can positively surprise the street estimates for CY25. Related-party transactions were mainly with SMV Group; however, the same remained stable and in-line with historical trends.

**Focused ESG investments driving cost savings and growth investments:** VBL is making focused ESG investments toward reduction of water usage, non-renewable energy, plastic, and sugar. In line with investments, the water usage ratio has declined to 1.56x (per liter of beverage produced) from 1.94x in CY19, with a target of reaching 1.40x by CY25. VBL is also light-weighting pre-forms/closures by 6-15% across SKUs vs CY15-19. VBL also aims to increase its r-PET usage to 30% by CY25, through backward integration and a JV with Indorama. VBL aims to service 25% of its utility needs via renewable resources by CY30 (from 16%/7% in CY24/CY20). Focused launches are also driving improved mix in favor of low/no-sugar products (53% vs 40% YoY).

**International business making a healthy bottom-line contribution:** International geographies are now contributing encouragingly to PAT, albeit the subsidiary PAT contribution dipped to ~16% in CY25 vs ~18% in CY24, whereas rev mix increased to ~33% due to South Africa acquisition (vs 25% in CY24). Lower PAT mix is likely due to weakness in Zimbabwe (sugar-tax) and current weak PAT profile of acquired SA business. Morocco continues to see strong momentum with 22% topline growth, Sri-Lanka has seen healthy growth acceleration (40% in CY24), while FX fluctuation/sugar-tax has likely impacted Zimbabwe/Zambia's profitability. Despite flat topline in Nepal, PAT expanded ~2.0x vs CY24 on better margins and lower tax. Despite heat waves impacting peak-CY24 season, India business saw decent PAT growth at ~30% on under penetration, expanded distribution, and a 200bps margin gain amid better revenue mix and cost-saving initiatives.

Varun Beverages: Financial Snapshot (Consolidated)										
Y/E (Rs mn)	CY22	CY23	CY24	CY25E	CY26E					
Revenue	131,731	160,426	200,077	256,420	309,124					
EBITDA	27,881	36,095	47,111	58,449	70,989					
Adj. PAT	14,975	20,559	25,946	35,845	45,625					
Adj. EPS (Rs)	4.6	6.3	8.0	10.6	13.5					
EBITDA margin (%)	21.2	22.5	23.5	22.8	23.0					
EBITDA growth (%)	68.5	29.5	30.5	24.1	21.5					
Adj. EPS growth (%)	115.8	37.3	26.2	32.7	27.3					
RoE (%)	32.6	34.2	22.0	19.7	21.0					
RoIC (%)	20.9	23.2	21.3	20.1	22.5					
P/E (x)	108.4	79.0	62.6	47.2	37.1					
EV/EBITDA (x)	59.6	46.4	34.6	27.9	22.9					
P/B (x)	31.8	23.4	9.8	8.6	7.1					
FCFF yield (%)	0.1	(0.6)	(1.1)	0.8	2.0					

Source: Company, Emkay Research

Target Price - 12M	Dec-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	67.4

Stock Data	VBL IN
52-week High (Rs)	683
52-week Low (Rs)	419
Shares outstanding (mn)	3,381.8
Market-cap (Rs bn)	1,618
Market-cap (USD mn)	18,549
Net-debt, FY26E (Rs mn)	(3,097.8)
ADTV-3M (mn shares)	8
ADTV-3M (Rs mn)	4,333.0
ADTV-3M (USD mn)	49.7
Free float (%)	36.0
Nifty-50	22,470.5
INR/USD	87.2
Shareholding, Dec-24	
Promoters (%)	60.2
FPIs/MFs (%)	25.3/7.0
, ( ,	_3.5,7.0

Price Performance									
(%)	1M	3M	12M						
Absolute	(10.5)	(26.0)	(15.9)						
Rel. to Nifty	(8.2)	(19.1)	(16.4)						



#### Devanshu Bansal

devanshu.bansal@emkayglobal.com +91-22-66121385

# Mohit Dodeja

mohit.dodeja@emkayglobal.com +91-22-66242481

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com) use and downloaded


# **Story in Charts**

Exhibit 1: VBL's peak-month capacity is ~65% higher ahead of CY25 season vs CY22 season; unseasonal rains in CY23 and excessive heat waves in CY24 impacted CY23/CY24 seasons

CY22-season	++Greenfield	++ Brownfield	CY25-season				
	1. Bundi (Rajasthan)	1. Pathankot					
	2. Jabalpur (MP)	2. Kosi					
	3. Supa (MH)	3. Bharuch					
	4. Gorakhpur (UP)	4. Tirunelveli					
Conneity (1 Ov)	5. Khordha (Orissa)	5. Begusarai	Campaity (1 6Ev)				
Capacity (1.0x)	6. Kangra (HP)	6. Guwahati	Capacity (1.65x)				
	7. Prayagraj (UP)	7. Gorakhpur					
	8. Buxar (Bihar)	8. Sri-City					
	9. Meghalaya	8. Morocco					
	10. DRC	9. Zimbabwe					


Source: Company, Emkay Research

Exhibit 2: Strong traction in Sting has enabled near-doubling of VBL's retail distribution reach




Source: Company, Emkay Research

Exhibit 3: Part consolidation of SA business in CY25 led to increase in NWC days, which should normalize going ahead



Source: Company, Emkay Research

Exhibit 4: VBL has done a capex of Rs100-110bn during CY21-CY25TD toward 10 greenfield and nine brownfield expansions



Source: Company, Emkay Research


Exhibit 5: With focused ESG initiatives, VBL is light-weighting its pre-forms/closures to drive cost savings and enable growth investments

Weight reduction (Pre-forms, grams)	2010-14	2015-19	2020-24	Reduction vs 2015-19 (%)
600ML	25.5	22.2	22.2	0.0
750ML	34.7	30.7	27.1	-11.7
1.0L	21.0	21.0	19.0	-9.5
1.25L	36.0	34.7	32.5	-6.3
2.25L	52.5	50.7	47.0	-7.3

Weight reduction (Closures, grams)	2010-14	2015-19	2020-24	Reduction vs 2015-19 (%)
CSD/Juice	3.15	2.75	2.35	-14.5
Water	1.7	1.5	1.35	-10.0

Source: Company, Emkay Research


Exhibit 6: Usage of low-cost renewable sources is increasing for VBL; the company targets 25% of overall energy consumption to be from renewable energy sources by CY30



Renewable Energy Consumption, (% of total consumption)

Source: Company, Emkay Research

Exhibit 8: Traction in Sting and other no- or low-sugar products is reducing the consumption of sugar in the business; further increase in mix of such products should drive margin gains



Source: Company, Emkay Research


Exhibit 7: Saving costs on the back of low water usage; VBL further targets reduced water consumption of 1.40 liter per liter of beverage produced by CY25



Water usage, liters (per liter of beverage produced)

Source: Company, Emkay Research; \* Steady state WUR was 1.54 times in 2023 and 1.50 times in 2024, the differential is on account of stabilization of 2 new greenfield plants in 2023 and 3 new greenfield plants in 2024

Exhibit 9: VBL has been investing in distribution expansion with  $\sim \! 10\%$  growth in its retail outlets; VBL added 1.5L Visi-Coolers in CY24 (up  $\sim \! 15\%$  YoY)



Source: Company, Emkay Research

Exhibit 10: Mix of low sugar and no sugar products has increased, in line with evolving consumer preferences for such products



Source: Company, Emkay Research

Exhibit 11: International business is making a healthy bottom-line contribution; CY24 PAT contribution of international subsidiaries is lower due to implementation of sugar-tax in Zimbabwe and low-margin profile in acquired SA region

Particulars (%)	Revenue Mix (%) PAT Mix (%)											
	CY19	CY20	CY21	CY22	CY23	CY24	CY19	CY20	CY21	CY22	CY23	CY24
India	76	72	71	77	75	67	100	55	61	78	82	84
Zimbabwe	8	11	11	7	9	8	-4	41	28	13	10	8
South-Africa	0	0	0	0	0	7	0	0	0	0	0	-1
Morocco	5	5	5	5	6	6	-4	-4	0	1	2	1
DMCC	0	0	0	1	2	4	0	0	0	2	1	1
Nepal	6	6	5	5	4	3	12	7	-3	2	3	5
Sri-Lanka	2	2	2	2	2	2	-1	-1	1	1	2	2
Zambia	2	2	3	3	2	2	-3	-10	6	1	-2	-1
Lunarmech	0	1	2	2	1	1	0	12	6	3	2	1
DRC	0	0	0	0	0	1	0	0	0	0	0	0
Others	0	0	0	0	0	0	0	0	0	0	0	0

Source: Company, Emkay Research, \*Revenue/PAT mix has been calculated as Revenue/PAT of respective subsidiaries divided by summation of standalone Revenue/PAT and Revenue/PAT of all subsidiaries, respectively

Exhibit 12: Major transactions have been toward sale/purchase of goods from the SMV Group; declining trend continues as RPT quantum remain 1-2% of sales vs 7.5% in CY19

Transactions with related parties (Rs mn)	CY16	CY17	CY18	CY19	CY20	CY21	CY22	CY23	CY24	Emkay Remarks
Sale of goods	470	349	220	251	732	403	571	411	335	Majorly with SMV Group, Jai Beverages DIL, and Deyani Foods (Creambell)
Sale of raw materials and stores	0	0	3	289	96	195	258	227	298	Majorly with SMV Group, Jai Beverages DIL, and Deyani Foods (Creambell)
Purchase of goods		1	1	905	600	768	991	960	741	Majorly with SMV Group, Devyani Foods (Creambell)
Purchase of raw materials and stores	582	465	763	625	0	93	94	77	13	Majorly with SMV Group, Devyani Foods (Creambell)
Travelling expenses paid	72	92	116	217	38	109	264	102	102	Travelling expenses paid to Wellness Holdings
Dividend paid	0	223	240	377	353	327	485	670	950	Dividends paid to promoters
Rent/lease charges paid	72	94	109	173	149	138	132	134	134	Majorly to holding company RJ Corp for leased properties
Other charges paid	47	332	89	222	178	168	0	42	107	Combination of multiple small charges - medical and utility
Loan/Interest received	50	52	-2	120	-4	-4	-2	-6	-4	Interest paid/received
Purchase of fixed assets	0	1,311	1,241	1,418	772	0	50	0	2	
Capital commitments	345	0	0	282	252	202	202	202	157	Part of territory acquisition from SMV Group
Bonus share issued	0	0	0	502	0	436	647	0	0	
Balance outstanding at the end of the year (net)	CY16	CY17	CY18	CY19	CY20	CY21	CY22	CY23	CY24	
Receivable/(payable), net	330	670	230	356	56	48	112	157	226	

Source: Company, Emkay Research

**Exhibit 13: Peer comparison** 

6	Price	Mcap	Reco	Target		EPS (Rs)		P/E (x)			EV/EBITDA (x)*		
Companies		(Rs bn)	кесо	Price (Rs)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Titan Company	3,005	2,690	Buy	4,300	37.6	55.3	71.4	79.9	54.4	42.1	48.6	36.3	29.5
Varun Beverages	484	1,637	Buy	800	8.0	10.6	13.5	60.6	45.7	35.9	34.7	28.0	23.0
Ethos	2,490	61	Buy	3,300	40.2	49.3	66.6	62.0	50.5	37.4	30.7	22.8	17.0
Aditya Vision	422	55	Buy	550	7.7	10.9	14.8	54.7	38.8	28.5	27.1	20.2	15.6
Page Industries	39,830	445	Reduce	40,000	630.9	696.3	834.1	63.1	57.2	47.7	40.6	36.7	30.9
ABFRL	241	293	Sell	280	-4.5	-1.2	-0.5	NA	NA	NA	18.6	13.5	11.0
Go Fashion	930	38	Buy	1,100	15.7	18.5	22.9	44.8	38.0	30.8	13.6	11.8	10.0
Jubilant FoodWorks	603	396	ADD	750	3.4	5.9	8.8	178.3	102.7	68.2	24.9	21.0	17.6
Devyani International	153	184	Reduce	170	0.3	0.7	1.3	438.8	225.9	119.6	22.6	18.2	14.8
Westlife Foodworld	681	106	BUY	875	0.9	5.4	10.2	717.1	125.9	66.7	31.2	22.9	17.8
Sapphire Foods	307	98	Buy	410	1.3	3.1	4.9	230.2	99.0	62.6	19.4	15.5	12.4
Senco Gold	260	42	Buy	600	15.5	15.6	19.8	16.8	16.7	13.2	14.6	9.3	7.5
Metro Brands	1,058	288	Buy	1,500	15.0	18.5	22.4	70.7	57.3	47.3	38.8	32.0	26.9

Source: Company, Emkay Research; Note: \*Post-IndAS116 EBITDA

# Varun Beverages: Consolidated Financials and Valuations

Profit & Loss					
Y/E (Rs mn)	CY22	CY23	CY24	CY25E	CY26E
Revenue	131,731	160,426	200,077	256,420	309,124
Revenue growth (%)	49.3	21.8	24.7	28.2	20.6
EBITDA	27,881	36,095	47,111	58,449	70,989
EBITDA growth (%)	68.5	29.5	30.5	24.1	21.5
Depreciation & Amortization	6,172	6,809	9,474	12,001	13,398
EBIT	21,710	29,286	37,637	46,448	57,591
EBIT growth (%)	93.3	34.9	28.5	23.4	24.0
Other operating income	-	-	-	-	-
Other income	388	794	1,213	1,000	2,700
Financial expense	1,861	2,681	4,504	0	0
PBT	20,237	27,398	34,346	47,448	60,291
Extraordinary items	0	0	0	0	0
Taxes	4,735	6,375	7,988	11,150	14,168
Minority interest	(527)	(464)	(411)	(452)	(498)
Income from JV/Associates	0	0	0	0	0
Reported PAT	14,975	20,559	25,946	35,845	45,625
PAT growth (%)	115.8	37.3	26.2	38.2	27.3
Adjusted PAT	14,975	20,559	25,946	35,845	45,625
Diluted EPS (Rs)	4.6	6.3	8.0	10.6	13.5
Diluted EPS growth (%)	115.8	37.3	26.2	32.7	27.3
DPS (Rs)	0.5	0.7	1.0	1.3	1.6
Dividend payout (%)	10.8	11.1	12.5	12.0	12.0
EBITDA margin (%)	21.2	22.5	23.5	22.8	23.0
EBIT margin (%)	16.5	18.3	18.8	18.1	18.6
Effective tax rate (%)	23.4	23.3	23.3	23.5	23.5
NOPLAT (pre-IndAS)	16,630	22,471	28,883	35,532	44,057
Shares outstanding (mn)	3,248	3,248	3,248	3,382	3,382

Source: Company, Emkay Research

Cash flows					
Y/E (Rs mn)	CY22	CY23	CY24	CY25E	CY26E
PBT (ex-other income)	19,848	26,605	33,133	46,448	57,591
Others (non-cash items)	0	0	0	0	0
Taxes paid	(4,478)	(6,314)	(6,539)	(10,418)	(13,327)
Change in NWC	(8,525)	(4,278)	(6,931)	(2,942)	(5,484)
Operating cash flow	14,879	25,503	33,641	45,089	52,178
Capital expenditure	(13,487)	(34,734)	(51,844)	(32,851)	(20,000)
Acquisition of business	-	(211)	(384)	0	0
Interest & dividend income	-	-	-	-	-
Investing cash flow	(13,098)	(34,152)	(51,016)	(31,851)	(17,300)
Equity raised/(repaid)	0	1	74,637	0	0
Debt raised/(repaid)	5,138	14,996	(28,301)	(23,643)	0
Payment of lease liabilities	0	0	0	0	0
Interest paid	(1,861)	(2,681)	(4,504)	0	0
Dividend paid (incl tax)	(1,624)	(2,273)	(3,249)	(4,301)	(5,475)
Others	(2,081)	414	(2,624)	1,060	946
Financing cash flow	(428)	10,456	35,959	(26,884)	(4,529)
Net chg in Cash	1,353	1,808	18,584	(13,646)	30,350
OCF	14,879	25,503	33,641	45,089	52,178
Adj. OCF (w/o NWC chg.)	23,403	29,781	40,572	48,031	57,662
FCFF	1,392	(9,231)	(18,204)	12,238	32,178
FCFE	(469)	(11,912)	(22,707)	12,238	32,178
OCF/EBITDA (%)	53.4	70.7	71.4	77.1	73.5
FCFE/PAT (%)	(3.1)	(57.9)	(87.5)	34.1	70.5
FCFF/NOPLAT (%)	8.4	(41.1)	(63.0)	34.4	73.0

Source: Company, Emkay Research

Balance Sheet					
Y/E (Rs mn)	CY22	CY23	CY24	CY25E	CY26E
Share capital	6,496	6,496	6,763	6,763	6,763
Reserves & Surplus	44,528	62,869	159,335	190,879	231,029
Net worth	51,024	69,365	166,098	197,642	237,792
Minority interests	1,131	1,482	1,298	1,298	1,298
Non current liab. & prov.	3,368	3,430	4,879	5,611	6,453
Total debt	40,649	56,118	29,155	7,025	8,469
Total liabilities & equity	96,173	130,394	201,431	211,576	254,011
Net tangible fixed assets	63,571	78,378	131,008	151,387	157,548
Net intangible assets	5,509	5,471	0	470	911
Net ROU assets	-	-	-	-	-
Capital WIP	6,066	19,222	11,667	11,667	11,667
Goodwill	242	242	3,009	3,009	3,009
Investments [JV/Associates]	-	211	595	595	595
Cash & equivalents	2,853	4,599	24,501	10,123	39,631
Current assets (ex-cash)	37,941	43,748	60,659	75,107	85,428
Current Liab. & Prov.	20,010	21,478	30,008	40,783	44,779
NWC (ex-cash)	17,932	22,271	30,651	34,324	40,649
Total assets	96,173	130,394	201,431	211,576	254,011
Net debt	37,797	51,519	4,655	(3,098)	(31,162)
Capital employed	96,173	130,394	201,431	211,576	254,011
Invested capital	87,254	106,363	164,668	189,191	202,118
BVPS (Rs)	15.7	21.4	51.1	58.4	70.3
Net Debt/Equity (x)	0.7	0.7	-	-	(0.1)
Net Debt/EBITDA (x)	1.4	1.4	0.1	(0.1)	(0.4)
Interest coverage (x)	11.9	11.2	8.6	0	0
RoCE (%)	26.0	27.4	24.0	23.6	26.6

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E	CY22	CY23	CY24	CY25E	CY26E
P/E (x)	108.4	79.0	62.6	47.2	37.1
P/CE(x)	76.8	59.3	45.8	35.3	28.6
P/B (x)	31.8	23.4	9.8	8.6	7.1
EV/Sales (x)	12.6	10.4	8.1	6.4	5.3
EV/EBITDA (x)	59.6	46.4	34.6	27.9	22.9
EV/EBIT(x)	76.5	57.2	43.3	35.1	28.3
EV/IC (x)	19.0	15.8	9.9	8.6	8.1
FCFF yield (%)	0.1	(0.6)	(1.1)	0.8	2.0
FCFE yield (%)	-	(0.7)	(1.4)	0.7	1.9
Dividend yield (%)	0.1	0.1	0.2	0.3	0.3
DuPont-RoE split					
Net profit margin (%)	11.4	12.8	13.0	14.0	14.8
Total asset turnover (x)	1.5	1.4	1.2	1.2	1.3
Assets/Equity (x)	1.9	1.9	1.4	1.1	1.1
RoE (%)	32.6	34.2	22.0	19.7	21.0
DuPont-RoIC					
NOPLAT margin (%)	12.6	14.0	14.4	13.9	14.3
IC turnover (x)	1.7	1.7	1.5	1.4	1.6
RoIC (%)	20.9	23.2	21.3	20.1	22.5
Operating metrics					
Core NWC days	49.7	50.7	55.9	48.9	48.0
Total NWC days	49.7	50.7	55.9	48.9	48.0
Fixed asset turnover	1.3	1.4	1.3	1.3	1.3
Opex-to-revenue (%)	31.3	31.3	31.9	32.8	32.7

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst	
11-Feb-25	520	800	Buy	Devanshu	Bansal
10-Jan-25	597	800	Buy	Devanshu	Bansal
13-Nov-24	568	750	Buy	Devanshu	Bansal
22-Oct-24	595	750	Buy	Devanshu	Bansal
03-Oct-24	588	700	Add	Devanshu	Bansal
31-Jul-24	631	660	Add	Devanshu	Bansal
23-Jul-24	620	640	Add	Devanshu	Bansal
07-Jul-24	646	640	Add	Devanshu	Bansal
14-May-24	596	660	Add	Devanshu	Bansal
07-Apr-24	598	600	Add	Devanshu	Bansal
17-Mar-24	574	600	Add	Devanshu	Bansal
06-Feb-24	539	560	Add	Devanshu	Bansal
10-Jan-24	507	460	Reduce	Devanshu	Bansal
20-Dec-23	501	460	Reduce	Devanshu	Bansal
30-Nov-23	442	460	Reduce	Devanshu	Bansal
06-Nov-23	378	460	Buy	Devanshu	Bansal
08-Oct-23	371	404	Buy	Devanshu	Bansal
03-Aug-23	329	388	Buy	Devanshu	Bansal
10-Jul-23	325	370	Buy	Devanshu	Bansal
25-May-23	324	370	Buy	Devanshu	Bansal
02-May-23	283	340	Buy	Devanshu	Bansal
09-Apr-23	279	332	Buy	Devanshu	Bansal

Source: Company, Emkay Research

## **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

March 13, 2025 | 8

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of March 13, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

## Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of March 13, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the March 13, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

# **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

# **Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### **OTHER DISCLAIMERS AND DISCLOSURES:**

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.